Patent-holding Patent Attorneys: Conflicts of Interest, Confidentiality, and Employment Issues

Will the Federal Circuit’s Eli Lilly v. Teva decision lead to efforts to abuse the modification provision of the Hatch-Waxman Act?

The Hatch-Waxman Act provides a mandatory thirty-month stay on the Food and Drug Administration’s (FDA) approval of an Abbreviated New Drug Application (ANDA) when a patent infringement suit is filed. The Act includes a provision for a district court to shorten or extend the Act’s thirty-month stay on FDA approval […]

By |2017-10-10T01:43:29-08:00January 1st, 2009|Academic Articles|
Go to Top